Aim: To assess the correlation between contrastenhanced computed tomography (CE-CT) and positronemission tomography (PET)/CT results and surgical and pathological findings in patients with recurrent platinumsensitive ovarian cancer who underwent secondary cytoreduction. Patients and Methods: 18 F-fluorodeoxyglucose ( 18 F-FDG) PET/CT with/without CE-CT were performed before 56 cytoreductive surgeries in 49 patients with suspicious recurrent ovarian cancer. Results: 18 F-FDG PET/CT showed higher sensitivity and diagnostic accuracy compared with CE-CT for both the whole series (100% versus 90.6%, respectively, and 97.8% versus 85.3%), and the 24 cases in which both examinations were performed (100% versus 87. 0% and, respectively, 95.8% versus 83.3%). The addition of CE-CT to 18 F-FDG PET/CT did not improve its diagnostic reliability. Conclusion: 18 F-FDG PET/CT appears to be the more reliable imaging technique for the evaluation of patients with suspicious recurrent ovarian cancer, and for the selection of those more suitable for secondary cytoreductive surgery.

No abstract

No abstract

Background/Aim: To assess the prognostic relevance of volume-based parameters [whole body (wb)metabolic tumor volume (MTV) and wb-total lesion glycolysis (TLG)] of pretreatment PET/CT in patients with potentially platinum-responsive recurrent ovarian cancer.Patients and Methods: This retrospective investigation analyzed 67 patients at first relapse. Results: At univariate analysis, post-relapse survival and overall survival correlated with residual disease after primary surgery (RD) (p=0.015 and 0.049, respectively), time to recurrence (p=0.005 and p=0.0003), number of recurrence sites (p=0.001 and p=0.0005), treatment at recurrence (p=0.044 and 0.043) and wb-MTV (p=0.023 and 0.021) but not with wb-TLG. RD, time to recurrence and number of recurrence sites, but not wb-MTV, were independent prognostic variables for post-relapse survival, and time to recurrence and number of recurrence sites, but not wb-MTV, were independent prognostic factors for overall survival. Conclusion: Volume-based parameters of PET/CT are not independent predictors of clinical outcome in potentially platinum-responsive recurrent ovarian cancer.